• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

贝叶斯网络虚拟筛选 CB(2) 受体激动剂和高通量对接:激动剂调节 G 蛋白偶联受体特征的结构见解。

Virtual screening of CB(2) receptor agonists from bayesian network and high-throughput docking: structural insights into agonist-modulated GPCR features.

机构信息

Laboratoire de Chimie Thérapeutique, Faculté des Sciences Pharmaceutiques et Biologiques, Université Lille-Nord de France, EA 4481, 3 rue du Professeur Laguesse, BP 83, 59006 Lille Cedex, France.

出版信息

Chem Biol Drug Des. 2013 Apr;81(4):442-54. doi: 10.1111/cbdd.12095.

DOI:10.1111/cbdd.12095
PMID:23217060
Abstract

The relevance of CB(2)-mediated therapeutics is well established in the treatment of pain, neurodegenerative and gastrointestinal tract disorders. Recent works such as the crystallization of class-A G-protein-coupled receptors in a range of active states and the identification of specific anchoring sites for CB(2) agonists challenged us to design a reliable agonist-bound homology model of CB(2) receptor. Docking-scoring enrichment tests of a high-throughput virtual screening of 140 compounds led to 13 hits within the micromolar affinity range. Most of these hits behaved as CB(2) agonists, among which two novel full agonists emerged. Although the main challenge was a high-throughput docking run targeting an agonist-bound state of a CB(2) model, a prior 2D ligand-based Bayesian network was computed to enrich the input commercial library for 3D screening. The exclusive discovery of agonists illustrates the reliability of this agonist-bound state model for the identification of polar and aromatic amino acids as new agonist-modulated CB(2) features to be integrated in the wide activation pathway of G-protein-coupled receptors.

摘要

在治疗疼痛、神经退行性和胃肠道疾病方面,CB(2)介导的治疗方法的相关性已得到充分证实。最近的一些工作,如一系列活性状态下的 A 类 G 蛋白偶联受体的结晶和 CB(2)激动剂的特定锚定位点的鉴定,促使我们设计了一种可靠的 CB(2)受体配体结合同源模型。对 140 种化合物进行高通量虚拟筛选的对接评分富集测试,在微摩尔亲和力范围内得到了 13 个命中化合物。这些命中化合物大多为 CB(2)激动剂,其中两种为新型完全激动剂。尽管主要的挑战是针对 CB(2)模型的配体结合状态进行高通量对接,但之前计算了基于配体的二维贝叶斯网络,以富集用于 3D 筛选的输入商业库。仅发现激动剂表明,这种配体结合状态模型对于鉴定极性和芳香族氨基酸作为新的激动剂调节的 CB(2)特征是可靠的,这些特征将被整合到 G 蛋白偶联受体的广泛激活途径中。

相似文献

1
Virtual screening of CB(2) receptor agonists from bayesian network and high-throughput docking: structural insights into agonist-modulated GPCR features.贝叶斯网络虚拟筛选 CB(2) 受体激动剂和高通量对接:激动剂调节 G 蛋白偶联受体特征的结构见解。
Chem Biol Drug Des. 2013 Apr;81(4):442-54. doi: 10.1111/cbdd.12095.
2
GPCR structure-based virtual screening approach for CB2 antagonist search.基于GPCR结构的虚拟筛选方法用于寻找CB2拮抗剂。
J Chem Inf Model. 2007 Jul-Aug;47(4):1626-37. doi: 10.1021/ci7000814. Epub 2007 Jun 20.
3
Structure-Based Prediction of G-Protein-Coupled Receptor Ligand Function: A β-Adrenoceptor Case Study.基于结构的 G 蛋白偶联受体配体功能预测:β-肾上腺素能受体案例研究。
J Chem Inf Model. 2015 May 26;55(5):1045-61. doi: 10.1021/acs.jcim.5b00066. Epub 2015 May 1.
4
Sulfonamide derivatives as new potent and selective CB2 cannabinoid receptor agonists.作为新型强效选择性CB2大麻素受体激动剂的磺胺衍生物
Bioorg Med Chem Lett. 2007 Sep 15;17(18):5133-5. doi: 10.1016/j.bmcl.2007.07.005. Epub 2007 Jul 10.
5
Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow.基于药效团的虚拟筛选工作流程发现新型CB2受体配体
J Med Chem. 2009 Jan 22;52(2):369-78. doi: 10.1021/jm801044g.
6
Homology modeling in tandem with 3D-QSAR analyses: a computational approach to depict the agonist binding site of the human CB2 receptor.串联同源建模与 3D-QSAR 分析:描绘人类 CB2 受体激动剂结合位点的计算方法。
Eur J Med Chem. 2011 Sep;46(9):4489-505. doi: 10.1016/j.ejmech.2011.07.023. Epub 2011 Jul 23.
7
Design, synthesis, and binding mode prediction of 2-pyridone-based selective CB2 receptor agonists.基于 2-吡啶酮的选择性 CB2 受体激动剂的设计、合成及结合模式预测。
Bioorg Med Chem. 2013 Apr 1;21(7):2045-55. doi: 10.1016/j.bmc.2013.01.006. Epub 2013 Jan 16.
8
7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as selective CB(2) cannabinoid receptor ligands: structural investigations around a novel class of full agonists.7-氧代-[1,4]恶嗪并[2,3,4-ij]喹啉-6-甲酰胺类化合物作为选择性 CB(2) cannabinoid 受体配体:新型全激动剂类化合物的结构研究。
J Med Chem. 2012 Jul 26;55(14):6608-23. doi: 10.1021/jm300763w. Epub 2012 Jul 11.
9
Development of fluorinated CB(2) receptor agonists for PET studies.氟代 CB2 受体激动剂的研发用于 PET 研究。
Bioorg Med Chem. 2013 Dec 1;21(23):7481-98. doi: 10.1016/j.bmc.2013.09.040. Epub 2013 Sep 24.
10
[Establishment of a high throughput screening model of cannabinoid receptor 2 agonist].[大麻素受体2激动剂高通量筛选模型的建立]
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012 Feb;28(2):194-6.

引用本文的文献

1
Artificial intelligence and machine-learning approaches in structure and ligand-based discovery of drugs affecting central nervous system.基于结构和配体的影响中枢神经系统药物发现中的人工智能和机器学习方法
Mol Divers. 2023 Apr;27(2):959-985. doi: 10.1007/s11030-022-10489-3. Epub 2022 Jul 11.
2
Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions.人工智能和机器学习辅助中枢神经系统疾病药物发现:现状与未来方向。
Med Res Rev. 2021 May;41(3):1427-1473. doi: 10.1002/med.21764. Epub 2020 Dec 9.
3
Intrabacterial Metabolism Obscures the Successful Prediction of an InhA Inhibitor of .
细菌内代谢掩盖了对一种InhA抑制剂的成功预测。
ACS Infect Dis. 2019 Dec 13;5(12):2148-2163. doi: 10.1021/acsinfecdis.9b00295. Epub 2019 Nov 5.
4
Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.大麻二酚和大麻二酚-二甲基庚基在大麻素受体 1 型和 2 型上的变构和正构药理学。
Br J Pharmacol. 2019 May;176(10):1455-1469. doi: 10.1111/bph.14440. Epub 2018 Aug 10.
5
Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design.通过化学信息学方法探索G蛋白偶联受体(GPCRs)配体空间:对合理药物设计的影响。
Front Pharmacol. 2018 Mar 9;9:128. doi: 10.3389/fphar.2018.00128. eCollection 2018.
6
Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis.构象限制导致一种对结肠炎具有口服活性的选择性CB2大麻素受体激动剂。
ACS Med Chem Lett. 2014 Dec 4;6(2):198-203. doi: 10.1021/ml500439x. eCollection 2015 Feb 12.
7
Bayesian models trained with HTS data for predicting β-haematin inhibition and in vitro antimalarial activity.使用高通量筛选(HTS)数据训练的贝叶斯模型,用于预测β-血红素抑制和体外抗疟活性。
Bioorg Med Chem. 2015 Aug 15;23(16):5210-7. doi: 10.1016/j.bmc.2014.12.020. Epub 2014 Dec 20.
8
Discovery of GPCR ligands for probing signal transduction pathways.用于探究信号转导途径的GPCR配体的发现。
Front Pharmacol. 2014 Nov 28;5:255. doi: 10.3389/fphar.2014.00255. eCollection 2014.
9
Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists.基于配体的虚拟筛选鉴定出一类选择性大麻素受体2激动剂。
Bioorg Med Chem. 2015 Jan 1;23(1):241-63. doi: 10.1016/j.bmc.2014.11.002. Epub 2014 Nov 8.
10
Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.综述:不止是一把锤子:配体“偏向性”与药物研发
Mol Endocrinol. 2014 Mar;28(3):281-94. doi: 10.1210/me.2013-1314. Epub 2014 Jan 16.